The results of two important lymphoma studies led by experts at Roswell Park will be presented during oral abstract sessions this morning at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California. Lymphoma is a type of blood cancer that causes white blood cells called lymphocytes to grow out of control and behave abnormally.
HealthTech Insights: Clinical Trial Supply and Logistics Market Size Expected to Reach USD 8.58 Bn by 2034
- – Study clarifies impact of CAR T-cell therapy in transformed follicular lymphoma
- Second details promising strategy for young patients with Hodgkin lymphoma
- Annual meeting of the American Society of Hematology underway in San Diego
“Our large multi-center study has revealed that cellular therapy results in demonstrably better outcomes for patients with transformed follicular lymphoma compared with patients with DLBCL,”
says Dr. Cortese.
HealthTech Insights: Global Clinical Trials Connect Conference 2025: Collaboration, Innovation and Enhancing Quality in Clinical Trials
The results of two important lymphoma studies led by experts at Roswell Park Comprehensive Cancer Center will be presented during oral abstract sessions this morning at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California. Lymphoma is a type of blood cancer that causes white blood cells called lymphocytes to grow out of control and behave abnormally.
Abstract 525: Improved survival in patients with transformed follicular lymphoma after CAR T-cell therapy
HealthTech Insights: Roswell Park Team Discovers New Treatment Target for Neuroendocrine Prostate Cancer
After receiving chimeric antigen receptor (CAR) T-cell therapy targeting CD19, a protein found on the surface of lymphoma cells, patients with relapsed or treatment-resistant transformed follicular lymphoma (tFL) had significantly better three-year overall survival and progression-free survival than patients newly diagnosed with diffuse large B-cell lymphoma (dnDLBCL) who received the same therapy. That’s the conclusion of a retrospective study led by Matthew Cortese, MD, MPH, Assistant Professor of Oncology in the departments of Medicine and Cancer Genetics & Genomics at Roswell Park. The research team also reports that CAR T-cell therapy appeared to overcome the poor outcomes associated with “double-hit” transformed follicular lymphoma, a rare and aggressive subtype.
HealthTech Insights: Roswell Park Team Identifies Factors That Boost Effectiveness of Immunotherapy in Recurrent Ovarian Cancer
Prior to this study, outcomes were largely unknown for patients with transformed follicular lymphoma who received CAR T-cell therapy. While the clinical trial data analyzed by the research team included outcomes in patients with transformed follicular lymphoma or newly diagnosed diffuse large B-cell lymphoma after CAR T-cell therapy, those trials had merged data from both groups and analyzed them together. Dr. Cortese and his colleagues teased out and analyzed the data that were specific to transformed follicular lymphoma, creating a clearer picture of how tFL patients respond to CAR T-cell therapy.
“Our large multi-center study has revealed that cellular therapy results in demonstrably better outcomes for patients with transformed follicular lymphoma compared with patients with DLBCL,” says Dr. Cortese. “The next steps will be to dive deeper into this question and try to explain why this significant difference exists, and to use these insights to develop better treatments for patients.”
HealthTech Insights: New Study Supports Fertility Low-Level Laser Therapy (LLLT) for Improving FET Success
The clinical trials enrolled 691 patients treated at 14 centers across the U.S. between 2015 and 2024, with median follow-up at 29.3 months. The retrospective study is the largest of its kind involving patients with transformed follicular lymphoma who were treated in the U.S.
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – prweb
